Thyroid Orbitopathy

TED Pathogenesis - Autoimmune Attack

• Primary Antigen: Thyrotropin receptor (TSH-R) on orbital fibroblasts & thyrocytes.
• Autoantibodies: TSH-R antibodies (TRAbs), particularly stimulating antibodies (TSI), cross-react with TSH-R on orbital fibroblasts.
• Orbital Fibroblast Activation: Leads to:
  • Adipogenesis (↑ fat volume).
  • Glycosaminoglycan (GAG) production (e.g., hyaluronic acid) → osmotic swelling.
  • Release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6).
• Immune Cells: T-cells & B-cells infiltrate orbit, perpetuating inflammation.
• Consequences: Muscle swelling, proptosis, optic nerve compression.

⭐ Orbital fibroblasts are the key effector cells in TED, differentiating into adipocytes and myofibroblasts, and producing excess GAGs under autoimmune stimulation, primarily by TSH-R antibodies and IGF-1R activation pathway.

📌 Mnemonic: TSH-R Antibodies Go For Orbits (TSH-R Antibodies, GAGs, Fibroblasts, Orbitopathy).

Clinical Showcase - Grave Signs

• Signs follow 📌 NOSPECS classification (severity increases down the list):
  • No signs/symptoms.
  • Only signs (no symptoms):
    • Lid retraction (Dalrymple's sign: stare).
    • Lid lag (von Graefe's sign: on downgaze).
  • Soft tissue involvement: Periorbital edema, chemosis, conjunctival injection, lid fullness.
  • Proptosis: Axial globe displacement > 21mm (Hertel exophthalmometer). Often asymmetric.
  • Extraocular muscle (EOM) involvement: Diplopia due to restrictive myopathy.
    • Common order of involvement: Inferior Rectus (IR), Medial Rectus (MR), Superior Rectus (SR), Lateral Rectus (LR) (📌 IMSLO).
  • Corneal involvement: Exposure keratopathy from proptosis & lid retraction; leads to punctate erosions, ulceration.
  • Sight loss (Optic Neuropathy): Due to optic nerve compression by enlarged EOMs at orbital apex. Presents with ↓ visual acuity, ↓ color vision, Relative Afferent Pupillary Defect (RAPD).

⭐ The Inferior Rectus is the most commonly affected extraocular muscle, leading to vertical diplopia (worse on upgaze) and restricted elevation of the eye.

Diagnostic Toolkit - Unmasking TED

• Clinical Suspicion: Proptosis, lid retraction (Darlymple's sign), diplopia, compressive optic neuropathy.
• Lab Confirmation:
  • TFTs: TSH, fT3, fT4 (patient may be hyper-, hypo-, or euthyroid).
  • Autoantibodies: TRAb (Thyroid Stimulating Hormone Receptor Ab) highly specific; Anti-TPO Ab.
• Orbital Imaging (CT/MRI):
  • Fusiform EOM belly enlargement, tendon sparing (key feature).
  • Apical crowding, optic nerve changes.
  • 📌 IMSLOw: Common EOM involvement order (Inferior > Medial > Superior > Lateral > Obliques).
• Activity Assessment:
  • Clinical Activity Score (CAS): Assesses 7 inflammatory parameters. Score ≥ 3/7 indicates active disease requiring potential immunomodulation.
• Severity Grading:
  • EUGOGO classification (Mild, Moderate-to-Severe, Sight-threatening).
  • NOSPECS classification (0-No signs/symptoms, 1-Only signs, 2-Soft tissue, 3-Proptosis, 4-EOM, 5-Cornea, 6-Sight loss).

⭐ In TED, extraocular muscle enlargement typically spares the tendons, a key differentiator from orbital myositis where tendons are often involved.

Treatment Playbook - Orbital Rescue

⭐ Teprotumumab, an IGF-1R inhibitor, is a significant advancement for active, moderate-to-severe Thyroid Eye Disease, reducing proptosis and diplopia.

High‑Yield Points - ⚡ Biggest Takeaways

• Most common cause of adult proptosis, often bilateral.
• Autoimmune, strongly linked to Graves' disease; can occur in euthyroid/hypothyroid states.
• Key pathology: Glycosaminoglycan (GAG) deposition and fibroblast proliferation in orbital tissues.
• NO SPECS mnemonic guides clinical assessment of severity.
• Inferior rectus (IR) and medial rectus (MR) most affected, causing diplopia and motility restriction.
• Dysthyroid Optic Neuropathy (DON) from apical compression is a major sight threat; smoking cessation is crucial_._